hVIVO is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases. Leveraging human disease models in influenza (flu), respiratory syncytial virus (RSV), human rhinovirus (HRV) and other respiratory indications. The hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO, has conducted human challenge studies for multiple clients, both large pharmaceutical and biotech and in a range of
challenge models using differing virus challenge agents.
hVIVO recruits volunteers in the UK to take part in it’s clinical human challenge studies using the ‘FluCamp’ brand.